In patients with hemophilia A, 42% of inhibitors were observed in patients with moderate hemophilia (FVIII activity, 1%-5%) and 25% in patients with FVIII activities between 6% and 10%, and 33% in those with higher FVIII activities (Figure). This evidence concerns the gene F8 and hemophilia A.